Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL-2: Follow-up after discontinuation of Efsubaglutide Alfa in overweight or obese individuals
ChiCTR2500105138Phase 2Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jun 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efsubaglutide alfa in obesity and Overweight, sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Percentage change in body weight at 24 weeks after Efsubaglutide Alfa withdrawal. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ChiCTR2500105138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105138.